Literature DB >> 12493022

Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in mucinous carcinoma of the breast: comparison with invasive ductal carcinoma.

S Matsukita1, M Nomoto, S Kitajima, S Tanaka, M Goto, T Irimura, Y S Kim, E Sato, S Yonezawa.   

Abstract

AIMS: Mucinous carcinoma of the breast usually shows less frequent lymph node metastasis and more favourable outcome compared with invasive ductal carcinoma. The aim of this study is to compare the expression profiles of several mucins in mucinous carcinomas and invasive ductal carcinomas to gain insight into the relationship between the less aggressive biological nature of mucinous carcinoma and the role of mucins. METHODS AND
RESULTS: We examined the expression profiles of MUC1 (membrane-bound mucin) of different glycoforms (from non-glycosylated form to fully glycosylated form), MUC2 (intestinal type secretory mucin), MUC5AC (gastric surface type secretory mucin) and MUC6 (gastric pyloric gland type secretory mucin) in 17 mucinous carcinomas and 46 invasive ductal carcinomas using immunohistochemistry. Various glycoforms of MUC1 were expressed frequently in both mucinous carcinomas (65-100%) and invasive ductal carcinomas (92-100%), although non-glycosylated MUC1 (MUC1/CORE) and fully glycosylated MUC1 (MUC1/HMFG-1) showed significantly lower expression rates in mucinous carcinomas compared with those in invasive ductal carcinomas. The expression rates of MUC2 (94%) and MUC6 (71%) in mucinous carcinomas were significantly higher than those of MUC2 (15%) and MUC6 (15%) in invasive ductal carcinomas. There was no significant difference in the expression rate of MUC5AC in mucinous carcinomas (12%) and that in invasive ductal carcinomas (4%).
CONCLUSIONS: The expression rate of MUC1/CORE and MUC1/HMFG-1, which is related to poor prognosis in the gastric and colorectal cancers, is low in mucinous carcinomas. The high expression rate of gel-forming secretory mucins (MUC2 and MUC6) in mucinous carcinoma suggests that high production of these types of mucins may act as a barrier to cancerous extension resulting in their less aggressive biological behaviour.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12493022     DOI: 10.1046/j.1365-2559.2003.01530.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  24 in total

Review 1.  Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy.

Authors:  Partha Mukhopadhyay; Subhankar Chakraborty; Moorthy P Ponnusamy; Imayavaramban Lakshmanan; Maneesh Jain; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2011-01-26

2.  Expression of vascular endothelial growth factor and caspase-3 in mucinous breast carcinoma and infiltrating ductal carcinoma-not otherwise specified, and the correlation with disease-free survival.

Authors:  Qiuli Wang; Lisha Sun; Jici Yan; Shuo Wang; Juncheng Zhang; Xinyu Zheng
Journal:  Oncol Lett       Date:  2017-08-10       Impact factor: 2.967

3.  Gastric gland mucin-specific O-glycan expression decreases as tumor cells progress from lobular endocervical gland hyperplasia to cervical mucinous carcinoma, gastric type.

Authors:  Kazuhiro Yamanoi; Keiko Ishii; Michihiko Tsukamoto; Shiho Asaka; Jun Nakayama
Journal:  Virchows Arch       Date:  2018-05-29       Impact factor: 4.064

4.  Precursor lesions of pancreatic cancer.

Authors:  Suguru Yonezawa; Michiyo Higashi; Norishige Yamada; Masamichi Goto
Journal:  Gut Liver       Date:  2008-12-31       Impact factor: 4.519

Review 5.  Mucin-rich salivary duct carcinoma with signet-ring cell feature ex pleomorphic adenoma of the submandibular gland: a case report of an unusual histology with immunohistochemical analysis and review of the literature.

Authors:  Kimihide Kusafuka; Matsuyoshi Maeda; Masatake Honda; Takashi Nakajima
Journal:  Med Mol Morphol       Date:  2012-03-20       Impact factor: 2.309

6.  Mucin 2 (MUC2) modulates the aggressiveness of breast cancer.

Authors:  Anna Astashchanka; Thomas M Shroka; Britta M Jacobsen
Journal:  Breast Cancer Res Treat       Date:  2018-10-13       Impact factor: 4.872

7.  Pure mucinous breast carcinoma: a favorable subtype.

Authors:  Meng Yang; Xin Li; Pang Chun-Hong; Huang Lin-Ping
Journal:  Breast Care (Basel)       Date:  2013-03       Impact factor: 2.860

8.  Primary Mucinous Cystadenocarcinoma of the Breast: Cytologic Finding and Expression of MUC5 Are Different from Mucinous Carcinoma.

Authors:  Sung Eun Kim; Ji Hye Park; Soonwon Hong; Ja Seung Koo; Joon Jeong; Woo-Hee Jung
Journal:  Korean J Pathol       Date:  2012-12-26

9.  Lynch syndrome-associated breast cancers do not overexpress chromosome 11-encoded mucins.

Authors:  Michael D Walsh; Margaret C Cummings; Sally-Ann Pearson; Mark Clendenning; Rhiannon J Walters; Belinda Nagler; John L Hopper; Mark A Jenkins; Graeme K Suthers; Jack Goldblatt; Kathy Tucker; Michael R Gattas; Julie L Arnold; Susan Parry; Finlay A Macrae; Michael A McGuckin; Joanne P Young; Daniel D Buchanan
Journal:  Mod Pathol       Date:  2013-02-01       Impact factor: 7.842

10.  Mucin expression in pleomorphic adenoma of salivary gland: a potential role for MUC1 as a marker to predict recurrence.

Authors:  T Hamada; S Matsukita; M Goto; S Kitajima; S K Batra; T Irimura; K Sueyoshi; K Sugihara; S Yonezawa
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.